Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

Dupixent is available as a solution inside single-dose prefilled pens and syringes, given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4 ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application ... the successful launch of Dupixent for chronic obstructive ...

Dupixent ® is now used to treat over a million ... up 1% based on preliminary (unaudited) results EYLEA HD pre-filled syringe (PFS) submission completed; launch expected by mid-2025 Libtayo ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label ... of care in the anti-VEGF category. Dupixent's ongoing growth is supported by recent ...